RESEARCH

Open Access



Ambient fine particulate matter and allergic symptoms in the middle-aged and elderly population: results from the PIFCOPD study

Shanshan Wei^{1†}, Jiping Liao^{1†}, Tao Xue², Kunyao Yu¹, Xiuhua Fu³, Ruiying Wang⁴, Xiaomin Dang⁵, Cheng Zhang¹, Hua Qiao⁶, Shujuan Jiang⁷, Jianhong Xiao⁸, Lixia Dong⁹, Jinzhi Yin¹⁰, Xixin Yan^{11,12}, Weihua Jia¹³, Guifang Zhang¹⁴, Rui Chen³, Bo Zhou⁵, Beibei Song^{11,12}, Jing Li⁴, Mengyu Yin⁹, Lina Zhang¹⁵, Liping Xie¹³, Shaochen Dong⁶, Jian Sun⁷, Peng Gao¹⁰, Bifang Miao⁸, Wei Li¹⁰, Lan He³, Qian Ning⁵, Limin Zhao¹⁶, Hengyi Liu², Han Cao¹⁷ and Guangfa Wang^{1*}

Abstract

Background The associations between short- and long-term exposure to ambient fine particulate matter with an aerodynamic diameter \leq 2.5 µm (PM_{2.5}) and allergic symptoms in middle-aged and elderly populations remain unclear, particularly in China, where most cities have severe air pollution.

Methods Participants (n = 10,142; age = 40–75 years) were recruited from ten regions in China from 2018 to 2021 for the Predictive Value of Inflammatory Biomarkers and Forced Expiratory Volume in 1 s (FEV₁) for Chronic Obstructive Pulmonary Disease (PIFCOPD) study. Short-term (lag0 and lag0–7 day) and long-term (1-, 3- and 5-year) $PM_{2.5}$ concentrations at residences were extracted from the air pollutant database known as Tracking Air Pollution (TAP) in China. Multivariate logistic regression models were used to estimate associations for short- and long-term $PM_{2.5}$ exposure concentrations and long-term exposure models were additionally adjusted for short-term deviations.

Results A 10 µg/m³ increase in PM_{2.5} on the day the allergic symptoms questionnaire was administered (lag0 day) was associated with higher odds of allergic nasal (1.09, 95% Cl 1.05, 1.12) and eye symptoms (1.08, 95% Cl 1.05, 1.11), worsening dyspnea caused by allergens (1.06, 95% Cl 1.02, 1.10), and ≥ 2 allergic symptoms (1.07, 95% Cl 1.03, 1.11), which was similar in the lag0–7 day concentrations. A 10 µg/m³ increase in the 1-year average PM_{2.5} concentration was associated with an increase of 23% for allergic nasal symptoms, 22% for eye symptoms, 20% for worsening dyspnea caused by allergens, and 21% for ≥ 2 allergic symptoms, similar to the 3- and 5-year average PM_{2.5} concentrations. These associations between long-term PM_{2.5} concentration and allergic symptoms were generally unchanged after adjustment for short-term deviations.

Conclusions Short- and long-term exposure to ambient $PM_{2.5}$ was associated with an increased risk of allergic nasal and eye symptoms, worsening dyspnea caused by allergens, and ≥ 2 allergic symptoms.

Trial registration Clinical trial ID: NCT03532893 (29 Mar 2018).

Keywords Ambient fine particulate matter, Allergic symptoms, Short- and long-term exposure

[†]Shanshan Wei and Jiping Liao have contributed equally to this work

*Correspondence: Guangfa Wang wangguangfa@hotmail.com Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

Ambient fine particulate matter with an aerodynamic diameter $\leq 2.5 \ \mu m \ (PM_{2.5})$ is detrimental to public health [1, 2]. Over the past decades, there has been growing evidence that ambient $PM_{2.5}$ exposure is a risk factor for developing and exacerbating asthma and allergic diseases [1, 3–8]. The global population-weighted $PM_{2.5}$ concentration increased from 39.7 $\mu g/m^3$ in 1990 to 44.2 $\mu g/m^3$ in 2015 [2]. There is growing concern that ambient $PM_{2.5}$ may contribute to the prevalence of allergic diseases and symptoms.

With rapid economic development, urbanization, and industrialization in recent decades, China has become one of the most polluted countries worldwide [2]. PM_{2.5} concentrations increased from 1990 and peaked during 2011–2013 [9]. In the wake of the air pollution crisis, the State Council of China promulgated the toughestever Air Pollution Prevention and Control Action Plan (APPCAP) in 2013 [10]. China initiated reductions in anthropogenic PM_{2.5} emissions in 2013, and populationweighted PM_{2.5} concentrations rapidly decreased by 4.51 μ g/m³/year from 2013 to 2016 [11]. However, as of the end of 2017, the entire Chinese population lived in areas with annual average PM2.5 concentrations exceeding 10 µg/m³ [12] (World Health Organization (WHO) interim target 4), and 81.1% lived in areas with concentrations above 35 μ g/m³ [13] (Chinese grade I ambient air-quality standard) [9]. In contrast to other countries, China is currently transitioning from high to low air pollution levels, which provides an excellent opportunity to study the effects of air pollution on human health.

Short-term exposure to air pollution can exacerbate preexisting asthma [1], allergic diseases [4], and chronic obstructive pulmonary disease (COPD) [14] and cause an increased risk of hospitalization or even mortality related to respiratory and allergic diseases. Long-term exposure to air pollution increases the risk of morbidity and mortality from asthma [1, 8] and allergic diseases [6, 15]. However, some studies did not report evidence of a positive association between ambient air pollution and asthma and allergic diseases [16, 17]. There is an urgent need to investigate the impact of short- and long-term air pollutant exposure on allergic symptoms in a large well-documented cohort with detailed covariate data.

Most published studies on ambient $PM_{2.5}$ exposure, allergic symptoms, and asthma were mainly performed in regions with relatively low air pollution concentrations [15, 18, 19] and young populations, such as children, adolescents, and young adults [16, 17]. However, more than 90% of air pollution-related deaths occur in Asia and Africa, where air pollution is generally a serious problem [10, 20]. In recent decades, the prevalence of allergic diseases such as asthma and allergic rhinoconjunctivitis has been increasing worldwide among older adults [8, 21]. The national cross-sectional China Pulmonary Health (CPH) study revealed that the prevalence of asthma increased with age, from 2.5% in individuals aged 20 to 39 years to 5.4% in those aged 40 years or older [21]. China, one of the countries most burdened by air pollution, is home to a fifth of the world's older people [22]. However, there is a lack of data with respect to the effect of ambient $PM_{2.5}$ exposure on allergic symptoms among middle-aged and elderly populations. Considering the burden of allergic diseases attributed to ambient air pollution exposure, a better understanding of whether middle-aged and elderly individuals are susceptible to this exposure should enable the design of prevention strategies.

Therefore, this study aimed to estimate the associations between allergic symptoms and short- and longterm ambient $PM_{2.5}$ exposure in the Predictive Value of Inflammatory Biomarkers and Forced Expiratory Volume in 1 s (FEV₁) for COPD (PIFCOPD) study, a nationwide prospective cohort study in China.

Methods

Study design and participants

The PIFCOPD study, an ongoing nationwide prospective cohort study, enrolled 10,385 middle-aged and elderly individuals without respiratory disease in China between May 2018 and October 2021. The studied population covered ten regions: Beijing, Jilin, Inner Mongolia, Shandong, Fujian, Hebei, Shanxi, Tianjin, Shaanxi, and Henan. Details of the study have been previously described [23]. After excluding individuals with ages outside the 40–75 year range (n=113) and those with at least one missing covariate (n=130), 10,142 participants (3756 men and 6386 women) were included in this study.

The study was approved by the ethics review committees of the Peking University First Hospital (2018 Number 31). Written informed consent was acquired from all participants.

Procedures

Data were collected at local branch health centers. Participants underwent medical examinations, including anthropometric measurements, spirometry, blood tests, and urinary tests. A series of standard self-administered questionnaires, including demographic, risk factors, lifestyle questionnaires, St George's Respiratory Questionnaire (SGRQ), and the allergic symptoms questionnaire [24] were administered by trained reviewers. In this study, data were collected on the nonperiod-specified prevalence of allergic nasal ("Do you sometimes have an itchy, runny, or stuffy nose?") and eye symptoms ("Do you sometimes have itchy, watery, swollen or burning eyes?"), wheezing ("Do you ever experience wheezing?") and worsening dyspnea caused by allergens ("Does exposure to dust, pollen, or pets make your shortness of breath worse?"). Education level was classified as no schooling or primary school, middle school, high school, and college or higher. Body mass index (BMI) was calculated by taking the participant's weight in kilograms divided by their height in meters squared. Passive smoking was defined as the exposure of a nonsmoker to smoke at home or in a work setting. Biomass exposure was defined as the daily use of wood or animal waste fuels for cooking or heating. Occupational exposure was defined as working in environments with remarkably harmful dust or fumes.

Exposure assessment

Ambient PM2.5 concentrations, extracted from the air pollutant database known as Tracking Air Pollution in China (TAP) [25], were estimated based on a two-stage machine learning model coupled with the synthetic minority oversampling technique and a tree-based gapfilling method. Daily PM_{2.5} concentrations in China with complete coverage at a spatial resolution of 10 km have been available since 2000. Details of the PM_{2.5} exposure assessment model have been described in our previous publications [11]. This model is comparable to models in other studies, and the average out-of-bag cross-validation R^2 for different years was 0.83 [26]. Residential PM_{2.5} exposure concentrations were estimated by assigning predicted PM_{2.5} concentrations to each participant's residential address. We defined short-term exposure as the daily average of a single 0 day (lag0 day) and the moving average of 0-to-7 day concentrations (lag0-7 day) before the day before the allergic symptoms questionnaire was administered. Long-term PM_{2.5} exposure was estimated by calculating the 1-, 3- and 5-year averages of the PM_{2.5} concentrations for the calendar year before administering the allergic symptoms questionnaire. We also obtained the daily average of the ambient temperature on the day the allergic symptoms questionnaire was administered (lag0 day) at a 9 km \times 9 km spatial resolution from the atmospheric reanalysis V5 (ERA5) Land dataset.

Statistical analyses

We compared baseline characteristics between the <2 allergic symptoms group and the ≥ 2 allergic symptoms group using the independent sample test-test for continuous variables and the χ^2 test for categorical variables. Multivariable logistic regression models were used to estimate associations between short- (lag0 and lag0–7 day) and long-term (1-, 3- and 5-year) PM_{2.5} concentrations at residences and self-reported allergic nasal and eye symptoms, worsening dyspnea caused by allergens and ≥ 2 allergic symptoms. Effect estimates

are presented as odds ratios (ORs) and their 95% confidence intervals (CIs) for each 10 μ g/m³ increase in the PM_{2.5} concentration. We gradually added potential confounders to observe their effects, and a total of four models were developed: Model 1, no adjustments; Model 2, adjusted for age, sex, education level (no schooling or primary school, middle school, high school, and college or higher), BMI (<25 kg/m², 25–29.9 kg/m², \geq 30 kg/ m²), geographic region (north, east, northeast, northwest), ambient temperature (lag0 day, average on the day the allergic symptoms questionnaire was administered), the season in which the allergic symptoms questionnaire was administered (winter and summer, spring and autumn); Model 3, further adjusted for cumulative smoking exposure (0, $1-19 \ge 20$ pack-years), passive smoking, biomass exposure, household cooking, and occupational exposure; and Model 4 (only for long-term exposure models), further adjusted for short-term PM₂₅ concentration deviations. In Model 4, we examined the influence of additional adjustments for short-term variations in long-term concentrations when estimating associations between allergic symptoms and long-term PM_{2.5} exposure, including the 1-, 3- and 5-year average concentrations. Short-term PM_{2.5} concentration deviations were defined for each participant as the absolute difference between the PM2.5 concentration on the day the allergic symptoms questionnaire was administered and the 1-, 3- and 5-year average concentrations. For example, the short-term PM_{2.5} concentration deviation for the model of the 1-year average PM_{2.5} concentration was calculated as follows: Short-term PM_{2.5} concentration deviation = PM_{25} concentration on the day the allergic symptoms questionnaire was administered-1-year average $\mathrm{PM}_{2.5}$ concentration. The associations between ambient PM2.5 exposure and wheezing were not analyzed in this study because the prevalence of wheezing was low, and the regression model could not be run after adjusting for a range of covariates.

All statistical analyses were performed using R version 4.1.2. All two-tailed tests were regarded as statistically significant at the 0.05 level.

Results

The distribution of 10,142 participants (6386 females and 3756 males) by general characteristics and risk factors is summarized in Table 1. The participants had a mean age of 59.27 years (range 40–75 years), most (65%) lived in the northern region, more than half (58%) cooked at home, and only 4.9% had biomass exposure. Among the participants, 9721 had one or no allergic symptoms, and the other 421 (4.2%) had more than one allergic symptom. There were significant differences in education level, passive smoking, smoking type,

ALL < 2 allergic symptoms \geq 2 allergic symptoms p-value N = 10,142N=9721 N = 4210.797 Sex Female 6386 (63) 6118 (63) 268 (64) Male 3756 (37) 3603 (37) 153 (36) 59.27 (8.41) 59.28 (8.42) 59.03 (8.17) 0.549 Age, y BMI aroup 0.684 $< 25 \text{ kg/m}^2$ 5938 (59) 5691 (59) 247 (59) 25-29.9 kg/m² 3548 (35) 3405 (35) 143 (34) \geq 30 kg/m² 656 (6.5) 625 (6.4) 31 (7.4) Education level < 0.001 1795 (18) No schooling or primary school 1824 (18) 29 (6.9) Middle school 4409 (45) 4555 (45) 146 (35) High school 2387 (24) 2236 (23) 151 (36) College or higher 1376 (14) 1281 (13) 95 (23) Passive smoking < 0.001 975 (9.6) 901 (9.3) 74 (18) 0.003 Smoking type 8234 (81) 7916 (81) 318 (76) Never smoker Former or current smoker 1908 (19) 1805 (19) 103 (24) Cumulative smoking exposure, pack-years 0.011 318 (76) 0 7916 (81) 8234 (81) 1 - 19706 (7.0) 668 (6.9) 38 (9.0) ≥20 1202 (12) 1137 (12) 65 (15) Biomass exposure 495 (4.9) 466 (4.8) 29 (6.9) 0.063 Household cooking 5896 (58) 5599 (58) 297 (71) < 0.001 699 (7.2) Occupational exposure 771 (7.6) 72 (17) < 0.001Family history of asthma 295 (2.9) 256 (2.6) 39 (9.3) < 0.001 Geographic region < 0.001 North 6627 (65) 6283 (65) 344 (82) East 1678 (17) 1647 (17) 31 (7.4) Northeast 768 (7.6) 724 (7.4) 44 (10) Northwest 1069 (11) 1067 (11) 2 (0.5) Season^a < 0.001 Winter 369 (3.8) 4 (1.0) 373 (3.7) Spring 1594 (16) 1525 (16) 69 (16) Summer 6325 (62) 6095 (63) 230 (55) Autumn 1850 (18) 1732 (18) 118 (28)

Table 1 Demographics and risk factors by allergic symptoms in the PIFCOPD population (N = 10, 142)

Data are presented mean (SD) for continuous variables and n (%) for categorical variables

^a Season in which the allergic symptoms questionnaire was administered. BMI, body mass index

cumulative smoking exposure (pack-years), household cooking, occupational exposure, family history of asthma, geographic region, and season between the two groups. The proportions of passive smokers (18% vs. 9.3%) and former or current smokers (24% vs. 19%) were higher in the \geq 2 allergic symptoms group than in the <2 allergic symptoms group. For education level, the proportion of participants with a high education level was low in the <2 allergic symptoms group. A total of 256 (2.6%) of the 9721 participants in the <2 allergic symptoms group and 39 (9.3%) of the 421 participants in the ≥ 2 allergic symptoms group had a family history of asthma. The proportion of participants who completed the allergic symptoms questionnaire in autumn was also higher in the ≥ 2 allergic symptoms group than in the <2 allergic symptoms group (28% vs. 18%). There was a higher proportion of household cooking (71% vs. 58%) and occupational exposure (17% vs. 7.2%) in the ≥ 2 allergic symptoms group. For allergic symptoms, eye symptoms had the highest prevalence (6.1%), followed by nasal symptoms (5.6%), worsening dyspnea caused by allergens (3.2%), and wheezing (1.2%) (Table 2).

The average residential $PM_{2.5}$ concentration was 35.19 $(27.32) \ \mu\text{g/m}^3$ (range 1–288 $\ \mu\text{g/m}^3$) on the day the allergic symptoms questionnaire was administered (lag0 day) and 34.73 (20.93) µg/m³ (range 2.00-197.12 µg/ m^3) for the moving average of 0-to-7 day (lag0-7 day). For long-term exposure, the 1-, 3- and 5-year annual average PM_{2.5} concentrations were 50.56 (15.27) μ g/m³, 54.08 (16.92) µg/m³, and 59.79 (17.88) µg/m³, respectively (Table 3). The results of our study showed that during 2013-2020, the annual average concentrations of PM_{2.5} among ten regions were 81.97 μ g/m³, 73.55 μ g/ m³, 67.21 μ g/m³, 62.35 μ g/m³, 58.53 μ g/m³, 49 μ g/m³, 46.09 μ g/m³, and 44.92 μ g/m³, respectively. The annual average PM_{2.5} concentration decreased by 45.2% from 2013 (81.97 μ g/m³) to 2020 (44.92 μ g/m³) among the ten regions (Additional file 1: Fig. S1). PM_{2.5} concentrations exhibited seasonal variation, with the highest concentration in winter (90.08 µg/m³, 5-year average), followed by autumn (56.26 μ g/m³), spring (55.33 μ g/ m³), and summer (44.99 μ g/m³) (Additional file 1: Fig. S2).

The results from the three models (Model 1, Model 2, and Model 3) all showed that allergic symptoms increased with higher short-term $PM_{2.5}$ exposure (Table 4). In adjusted Model 3, the ORs of allergic symptoms per 10 µg/m³ increase in lag0 day average $PM_{2.5}$ concentration were 1.09 (95% CI 1.05, 1.12) for allergic nasal symptoms, 1.08 (95% CI 1.05, 1.11) for allergic eye symptoms, 1.06 (95% CI 1.02, 1.10) for worsening dyspnea caused by allergens, and 1.07 (95% CI 1.03, 1.11) for ≥ 2 allergic symptoms. The effect

Table 3 Distribution of the estimated ambient temperature and PM_{25} concentrations at residence

	Mean (SD)	Median (IQR)	Range
Short-term PM _{2.5} , µg/m ³			
Lag0 day	35.19 (27.32)	30.00 (25.00)	1.00 to 288.00
Lag0–7 day	34.73 (20.93)	31.75 (22.00)	2.00 to 197.12
Long-term PM _{2.5} , µg/m ³			
1-year	50.56 (15.27)	49.84 (20.47)	10.93 to 86.50
3-year	54.08 (16.92)	53.09 (23.64)	13.43 to 93.32
5-year	59.79 (17.88)	59.41 (23.71)	15.45 to 100.35
Ambient temperatureª, ℃	20.81 (7.88)	23.08 (7.61)	- 19.03 to 32.76

^a Average on the day the allergic symptoms questionnaire was administered. $PM_{2,sr}$ particulate matter with an aerodynamic diameter \leq 2.5 µm

estimates were similar to those obtained using the $PM_{2.5}$ data of the lag0–7 day concentrations.

There were positive associations between long-term PM_{2.5} concentrations (1-, 3- and 5-year average) and allergic symptoms (Table 5). Compared with the 3- and 5-year average $PM_{2,5}$ concentrations, the 1-year average PM_{2.5} concentration had a stronger impact on allergic symptoms in the four long-term exposure models. In Model 3, each 10 μ g/m³ increase in the 1-year average PM_{2.5} concentration was associated with higher odds of allergic nasal (1.23, 95% CI 1.14, 1.33) and eye symptoms (1.22, 95% CI 1.13, 1.31), worsening dyspnea caused by allergens (1.20, 95% CI 1.09, 1.32) and ≥ 2 allergic symptoms (1.21, 95% CI 1.11, 1.32); these effect estimates were similar to those after adjustment for short-term PM_{2.5} concentration deviations in Model 4. Specifically, the OR of allergic eye symptoms for a $10 \ \mu g/m^3$ increase in the 1-year average concentration

Table 2 Allergic symptoms prevalence in the PIFCOPD study population

Questionnaire items	N (%)
Does not sometimes have an itchy, runny, or stuffy nose	9576 (94)
Does sometimes have an itchy, runny or stuffy nose	566 (5.6)
Allergic eye symptoms	
Does not sometimes have itchy, watery, swollen or burning eyes	9520 (94)
Does sometimes have itchy, watery, swollen or burning eyes	622 (6.1)
Wheezing	
Has not had wheezing symptoms	10,022 (99)
Has had wheezing symptoms	120 (1.2)
Worsening dyspnea caused by allergens	
Has not had worsened shortness of breath due to exposure to dust, pollen, or pets	9813 (97)
Has had worsened shortness of breath due to exposure to dust, pollen or pets	329 (3.2)
≥2 allergic symptoms	421 (4.2)

Data are presented as n (%)

was 1.22 (95% CI 1.13, 1.31) based on Model 3, compared with that of 1.22 (95% CI 1.14, 1.32) in Model 4 after adjustment for short-term $PM_{2.5}$ concentration deviations. Compared with long-term $PM_{2.5}$ concentration, the short-term $PM_{2.5}$ concentration deviations had a weaker impact on allergic symptoms in model 4. Each 10 µg/m³ increase in the 1-year short-term $PM_{2.5}$ concentration deviation, the risk increased by 7% for allergic nasal symptoms (1.07, 95% CI 1.04, 1.10), 6% for allergic eye symptoms (1.06, 95% CI 1.03, 1.09), 5% for worsening dyspnea caused by allergens (1.05, 95% CI 1.01, 1.09), 6% for ≥ 2 allergic symptoms (1.06, 95% CI 1.02, 1.10), these effect estimates were similar to those in 3- and 5-year average $PM_{2.5}$ concentration logistic regression models (Additional file 1: Tables S3–S5).

In addition to PM_{2.5} exposure, the ORs for the other covariates were similar in short- and long-term PM₂₅ concentrations models (Additional file 1: Tables S1–S5). Specifically, multivariable logistic regression showed that ≥ 2 allergic symptoms was associated with older age (1.03, 95% CI 1.01, 1.04), higher education level (middle school (2.20, 95% CI 1.46, 3.41); high school (3.38, 95% CI 2.24, 5.27); college or higher (4.34, 95% CI 2.78, 6.96)), passive smoking (2.22, 95% CI 1.65, 2.97), household cooking (1.53, 95% CI 1.20, 1.96), occupational exposure (1.42, 95% CI 1.06, 1.88) and family history of asthma (2.95, 95% CI 2.02, 4.21) in the 1-year average PM_{2.5} concentration logistic regression model 4 (Additional file 1: Table S3), which was similar to that of allergic nasal and eye symptoms, and worsening dyspnea caused by allergens.

Discussion

In the PIFCOPD study, short- and long-term ambient PM_{2.5} exposure levels were significantly associated with allergic symptoms, apart from other individual risk factors, including older age, higher education level, passive smoking, household cooking, occupational exposure, and family history of asthma. The associations between PM_{2.5} exposure and allergic symptoms, including allergic nasal and eye symptoms, worsening dyspnea caused by allergens, and ≥ 2 allergic symptoms, were stronger for the 1-, 3- and 5-year concentrations than the lag0 day, and lag0-7 day concentrations. Adjusting for shortterm PM_{2.5} concentration deviations had little effect on the estimated associations with long-term exposures. Our study provides new evidence of the health effects of ambient PM_{25} exposure in relation to the prevalence of allergic symptoms in the middle-aged and elderly Chinese population.

China is experiencing a transition period from high to low air pollution levels. The PM_{2.5} concentration trends in our study were consistent with previous reports [27, 28]. As the focus of the APPCAP, a remarkable decline in the annual average $PM_{2.5}$ concentration was achieved [28], with yearly concentrations decreasing by 45.2% (from 2013 to 2020) in our study. However, the short- and long-term exposure concentrations were considerably higher than the current Chinese grade I ambient airquality standard [13] or the WHO interim target 4 [12] in this study. Winter is the most severe season for ambient $PM_{2.5}$ air pollution [27]. A total of 8464 (83.5%) participants lived in northern, northeastern, and northwestern geographic regions, where coal burning is needed for heating in winter, emitting massive anthropogenic air pollutants.

Consistent with our study, previous studies showed that the prevalence of allergic symptoms and diseases increased when ambient air pollutants such as PM25 were high [21, 29, 30]. Experimental exposure to PM_{25} could directly impair the barrier function of epithelial cells and induce oxidative stress and inflammatory responses [31], thereby leading to allergic symptoms. Moreover, particulate matter contains many potential allergen carriers, such as pollutants, aerosols, pollens, bacteria, and fungi [32, 33], and interacts with allergens to enhance their immunogenicity [34, 35]. In addition, particulate matter also has an adjuvant effect on the production of immunoglobulin E (IgE) to common environmental allergens [36]. The synergistic biological effects induced by allergens and ambient PM2.5 could be one of the potential mechanisms illustrating the increasing risk of allergic diseases and symptoms at high PM_{2.5} exposure levels.

Air pollution contributes to the onset and aggravation of allergic symptoms or diseases [21, 35, 37]. Most previous studies were conducted on children and young adults [7, 19, 30]. However, few studies have examined the associations between ambient PM2.5 exposure and allergic nasal or eye diseases among middle-aged and elderly populations in large well-documented cohorts. Our study revealed that short- and long-term ambient PM_{2.5} exposure is positively associated with allergic nasal and eye symptoms among middle-aged and elderly populations. Consistent with our results, one study from Fukuoka showed that an interquartile range (IQR) increase in PM_{25} at lag0 day was associated with allergic nasal (1.08, 95% CI 1.03, 1.13) and eye (1.10, 95% CI 1.04, 1.16) symptoms among 2317 schoolchildren [7]. Ambient PM₂₅ exposure might alter tear film stability, causing the film to break up and thin by disrupting the tear lipid layer, thus causing eye irritation and discomfort [38]. According to a hospital-based population study in Japan, the ambient PM2.5 concentration was associated with the number of outpatient visits for allergic conjunctivitis during the nonpollen season [4]. The China, Children, Homes

Table 4 Associations between short-term PW_{25} exposures and allergic symptoms in the PIFCOPD study populatio	Table 4	Associations between s	hort-term PM ₂₅ exposi	ures and allergic symptom	is in the PIFCOPD study population
--	---------	------------------------	-----------------------------------	---------------------------	------------------------------------

	Mode 1		Model 2		Model 3	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Allergic nasal symptoms						
Lag0 day	1.08 (1.06, 1.11)	< 0.001	1.09 (1.06, 1.12)	< 0.001	1.09 (1.05, 1.12)	< 0.001
Lag0–7 day	1.1 (1.06, 1.14)	< 0.001	1.11 (1.06, 1.16)	< 0.001	1.11 (1.06, 1.16)	< 0.001
Allergic eye symptoms						
Lag0 day	1.08 (1.05, 1.10)	< 0.001	1.08 (1.05, 1.11)	< 0.001	1.08 (1.05, 1.11)	< 0.001
Lag0–7 day	1.13 (1.09, 1.16)	< 0.001	1.15 (1.11, 1.20)	< 0.001	1.16 (1.11, 1.20)	< 0.001
Worsening dyspnea caused by allergens						
Lag0 day	1.07 (1.04, 1.10)	< 0.001	1.06 (1.02, 1.10)	0.002	1.06 (1.02, 1.10)	0.002
Lag0–7 day	1.09 (1.04, 1.13)	< 0.001	1.06 (1.00, 1.11)	0.049	1.06 (1.00, 1.12)	0.06
\geq 2 allergic symptoms						
Lag0 day	1.07 (1.04, 1.10)	< 0.001	1.07 (1.04, 1.10)	< 0.001	1.07 (1.03, 1.11)	< 0.001
Lag0–7 day	1.09 (1.05, 1.13)	< 0.001	1.09 (1.03, 1.14)	0.001	1.09 (1.03, 1.14)	0.002

Effect estimates are presented as odds ratios (ORs) and their 95% confidence intervals (Cls) for each 10 μ g/m³ increase in the PM_{2.5} concentration. Model 1, no adjustments; Model 2, adjusted for age, sex, education level (no schooling or primary school, middle school, high school, and college or higher), BMI (<25 kg/m², 25-29.9 kg/m²), geographic region (north, east, northwest), ambient temperature (lag0 day, average on the day the allergic symptoms questionnaire was administered), the season in which the allergic symptoms questionnaire was administered (winter and summer, spring and autumn); Model 3, further adjusted for cumulative smoking exposure (0, 1–19, \geq 20 pack-years), passive smoking, biomass exposure, household cooking, and occupational exposure. PM_{2.5}, particulate matter with an aerodynamic diameter \leq 2.5 µm

	Model 1		Model 2		Model 3		Model 4	
	OR (95% CI)	p-value						
Allergic nasal symptoms	5							
1-Year	1.25 (1.18, 1.33)	< 0.001	1.25 (1.17, 1.35)	< 0.001	1.23 (1.14, 1.33)	< 0.001	1.23 (1.14, 1.33)	< 0.001
3-Year	1.14 (1.09, 1.20)	< 0.001	1.14 (1.07, 1.22)	< 0.001	1.13 (1.06, 1.21)	< 0.001	1.14 (1.07, 1.22)	< 0.001
5-Year	1.14 (1.09, 1.20)	< 0.001	1.12 (1.05, 1.19)	< 0.001	1.11 (1.04, 1.19)	0.001	1.13 (1.06, 1.20)	< 0.001
Allergic eye symptoms								
1-Year	1.23 (1.16, 1.30)	< 0.001	1.24 (1.16, 1.33)	< 0.001	1.22 (1.13, 1.31)	< 0.001	1.22 (1.14, 1.32)	< 0.001
3-Year	1.17 (1.11, 1.23)	< 0.001	1.2 (1.12, 1.27)	< 0.001	1.2 (1.12, 1.28)	< 0.001	1.21 (1.13, 1.29)	< 0.001
5-Year	1.17 (1.12, 1.23)	< 0.001	1.17 (1.11, 1.24)	< 0.001	1.17 (1.10, 1.25)	< 0.001	1.19 (1.12, 1.26)	< 0.001
Worsening dyspnea caused by allergens								
1-Year	1.26 (1.17, 1.37)	< 0.001	1.2 (1.10, 1.32)	< 0.001	1.2 (1.09, 1.32)	< 0.001	1.2 (1.09, 1.32)	< 0.001
3-Year	1.17 (1.09, 1.25)	< 0.001	1.09 (1.01, 1.19)	0.033	1.1 (1.01, 1.20)	0.032	1.1 (1.01, 1.20)	0.026
5-Year	1.17 (1.10, 1.25)	< 0.001	1.08 (1.00, 1.17)	0.057	1.08 (1.00, 1.17)	0.062	1.09 (1.00, 1.18)	0.041
≥2 allergic symptoms								
1-Year	1.24 (1.16, 1.33)	< 0.001	1.22 (1.12, 1.33)	< 0.001	1.21 (1.11, 1.32)	< 0.001	1.21 (1.11, 1.32)	< 0.001
3-Year	1.14 (1.08, 1.21)	< 0.001	1.11 (1.03, 1.20)	0.006	1.11 (1.03, 1.21)	0.006	1.12 (1.04, 1.21)	0.004
5-Year	1.15 (1.08, 1.21)	< 0.001	1.09 (1.02, 1.17)	0.012	1.1 (1.02, 1.18)	0.015	1.11 (1.03, 1.19)	0.007

Table 5 Associations between long-term PM₂₅ exposures and allergic symptoms in the PIFCOPD study population

Effect estimates are presented as odds ratios (ORs) and their 95% confidence intervals (Cls) for each 10 μ g/m³ increase in the PM_{2.5} concentration. Model 1, no adjustments; Model 2, adjusted for age, sex, education level (no schooling or primary school, middle school, high school, and college or higher), BMI (< 25 kg/m², 25–29.9 kg/m²), geographic region (north, east, northeast, northwest), ambient temperature (lag0 day, average on the day the allergic symptoms questionnaire was administered), the season in which the allergic symptoms questionnaire was administered (no runulative smoking exposure (0, 1–19, ≥ 20 pack-years), passive smoking, biomass exposure, household cooking, and occupational exposure; and Model 4, further adjusted for short-term PM_{2.5} concentration deviations. PM_{2.5}, particulate matter with an aerodynamic diameter ≤ 2.5 μ m

and Health (CCHH) project revealed that each 10 μ g/m³ increase in the annual PM_{2.5} concentration was associated with a 20% increase in the prevalence of allergic rhinitis among preschool children in six Chinese cities [30]. Short-term PM_{2.5} exposure levels were correlated with nasal lavage fluid eosinophils and exudation mediators in children with asthma in Paris [19]. PM_{2.5} can increase inflammatory cytokines, induce pathological damage to the nasal mucosa and conjunctival epithelium, and worsen nasal and eye symptoms [39, 40]. Improved air quality might reduce the inflammatory response and reduce allergic diseases and symptoms [41].

Exposure to high levels of ambient PM_{2.5} is a potential aggravating factor for allergic respiratory symptoms or diseases [1, 42]. Wheezing and worsening dyspnea caused by allergens are common allergic respiratory symptoms [43, 44]. The prevalence of allergic respiratory symptoms was 9-20.4% in a previous study [42, 44, 45], compared to that of 1.2% for wheezing and 3.2% for worsening dyspnea caused by allergens in this study. The discrepancy might be attributed to the exclusion of individuals with chronic respiratory diseases such as COPD, emphysema, asthma, and other conditions from this study. Consistent with previous studies [5, 42, 46], our study found a positive association between PM_{2.5} exposure and worsening dyspnea caused by allergens. A combined analysis of cross-sectional data from Lifelines and UK Biobank cohorts, each 5 μ g/m³ increase in the PM₂₅ concentration was associated with an increase of 16% for wheezing and 61% for shortness of breath [42]. PM_{25} exposure, either alone or in combination with allergic sensitization, can induce oxidative stress, signal transduction interference, enzyme inhibition, epigenetic dysregulation, airway hyperresponsiveness and remodeling [47]. Allergic respiratory symptoms can decrease with air quality improvement [48] and smoking cessation [49].

Our study found long-term PM_{2.5} exposure was more strongly associated with allergic symptoms than shortterm PM₂₅ exposure. The findings in our study could be attributable in part to differences between long- and short-term ambient PM2.5 exposure levels. Ambient PM_{2.5} exhibited the highest concentration in winter (90.08 μ g/m³, 5-year average) and the lowest concentration in summer (44.99 μ g/m³, 5-year average). Among the participants, 6325 (62%) were enrolled in the study in the summer, and only 373 (3.7%) were enrolled in the winter. The short-term (lag0 and lag0-7 day concentrations) ambient PM_{2.5} exposure levels were lower than the long-term (1-, 3- and 5-year average concentrations) in this study. Meanwhile, the questionnaire collected nonperiod-specified rather than recent allergic symptoms, which may be another important reason for the stronger associations for long-term than short-term PM_{25} exposure.

Short-term ambient PM2.5 concentration deviations might not significantly affect on long-term PM_{2.5} exposure models. Consistent with our results, a study of the LuftiBus cohort adjusting for short-term variations in nitrogen dioxide (NO₂) and PM_{2.5} concentrations had little effect on the estimated associations between air pollution exposure and lung function parameters in long-term exposure models [50]. Other studies adjusted for previous single-day or moving average concentrations instead of short-term deviations and revealed that the conclusions of associations between lung function parameters and long-term air pollution exposure were not altered [51, 52]. Therefore, it might not be necessary to adjust for short-term air pollution concentrations, including shortterm deviations, previous single-day or moving average concentrations, when estimating the effect of long-term ambient air pollution exposure.

Allergic diseases, which involve complex interactions of genetic, ethnic, environmental, and socioeconomic status or lifestyle risk factors, are primarily attributed to environmental factors such as indoor and outdoor air pollution, tobacco smoke exposure, and exposure to other pollutants [21, 37, 44, 53]. In addition to ambient PM_{2.5} exposure, we also found that allergic symptoms were positively associated with older age, higher education level, passive smoking, household cooking, occupational exposure and family history of asthma. Household cooking and tobacco smoke are major sources of indoor air pollution. Chinese cooking emits more PM_{2.5} than Western cooking [54]. For risk factors for allergic symptoms, previous studies have mainly focused on cooking fuel but not cooking itself [55]. In this study, a total of 58% (5896/10142) of the participants cooked frequently at home, only 4.9% (495/10142) had biomass exposure, and 84% (4969/5896) had kitchen ventilation. Household cooking itself, not cooking fuel, is a major risk factor for allergic symptoms. Despite smoking bans in public places in China, 9.6% of the participants in our study were still exposed to environmental tobacco smoke at home or in the workplace. We found that passive smoking was associated with increased allergic symptoms. Consistent with our results, a study based on the Respiratory Health in Northern Europe (RHINE) cohort revealed that passive smoking increased the risk of wheezing (1.26, 95% CI 1.02, 1.57) [56]. Family history of asthma is a well-known risk factor for asthma [53]. This study found that a history of asthma in close relatives is also a risk factor for nasal symptoms, eye symptoms, worsening dyspnea caused by allergens, and ≥ 2 allergic symptoms.

Several limitations of this study should be addressed. First, given the study design, it is challenging to provide causal inferences about the associations between $PM_{2.5}$ exposure and allergic symptoms. Further intervention and prospective studies are needed to verify the causality of the association in this study. Second, allergic symptoms were assessed by self-report questionnaires, making the study prone to recall bias. Third, as an issue commonly reflected in other studies, $PM_{2.5}$ exposure concentrations were only estimated at the residence due to a need for more information about work addresses or time-activity patterns. This might result in misclassification. Limited by data availability, information about other ambient pollutants was not available, and we could not distinguish between associations due to $PM_{2.5}$ specifically or other correlated pollutants.

Conclusions

In conclusion, the findings from the PIFCOPD study showed that short- and long-term ambient $PM_{2.5}$ exposure might have adverse effects on allergic symptoms among the middle-aged and elderly population in China, apart from other individual risk factors, including older age, higher education level, passive smoking, household cooking, occupational exposure and family history of asthma. Our findings contribute substantially to the evidence of adverse effects of ambient $PM_{2.5}$ exposure on allergic symptoms in middle-aged and elderly populations. This study further supports for the urgent need to control air pollution to protect middle-aged and elderly adults.

Abbreviations

APPCAP	Air Pollution Prevention and Control Action Plan
BMI	Body mass index
Cls	Confidence intervals
COPD	Chronic obstructive pulmonary disease
CPH	China Pulmonary Health
ERA5	The atmospheric reanalysis V5
FEV ₁	Forced expiratory volume in 1 s
IgE	Immunoglobulin E
IQR	Interquartile range
ORs	Odds ratios
PIFCOPD	Predictive Value of Inflammatory Biomarkers and FEV ₁ for COPD
PM ₂₅	Particulate matter with an aerodynamic diameter \leq 2.5 μ m
SGRQ	St George's Respiratory Questionnaire
TAP	Tacking Air Pollution
WHO	World Health Organization

Supplementary Information

The online version contains supplementary material available at https://doi. org/10.1186/s12931-023-02433-2.

Additional file 1: Figure S1. Trends in annual average PM2.5 concentrations among ten regions from 2013 to 2020 year. Figure S2. Season average PM2.5 concentrations of 1-, 3- and 5-year. Table S1. Estimated risks of each independent variable in the lag0 day PM2.5 concentration logistic regression model 3. Table S2. Estimated risks of each independent variable in the lag0-7 day PM2.5 concentration logistic regression model 3. **Table S3.** Estimated risks of each independent variable in the 1-year average PM2.5 concentration logistic regression model 4. **Table S4.** Estimated risks of each independent variable in the 3-year average PM2.5 concentration logistic regression model 4. **Table S5.** Estimated risks of each independent variable in the 5-year average PM2.5 concentration logistic regression model 4.

Acknowledgements

We thank the participants of Predictive Value of Inflammatory Biomarkers and FEV1 for COPD. For continuous support, assistance, and cooperation, we thank Yunxia Wang, Zhu Tian, Meng Wu, Xiaoyu Ma, Chunbo Zhang, Meng Zhang, Peining Zhou, Jingya Sun, Yishan Nie (Peking University First Hospital), Yi Wang, Lina Zhang (Shichahai Community Health Service Center), Xiaofei Wang (Xitian'gezhuang Community Health Service Center), Wen Han, Tingting Li, Qin Peng (Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University), Hongmin Yu (The First Hospital of Qinhuangdao), Yanzhi Liu (Hongguang Livable Community Health Service Center), Jiao Zhang (Linheli Second Community Health Service Station), Suvan Liu (Tianiin Medical University General Hospital), Zhaoiun Fan (Ciming Health Examination Management Group Tianjin Co., Ltd), Jing Chen (Heping District Xinxing Street Community Health Service Center), Xuhong Wang, Yonggang Li (General Hospital of Taiyuan Iron & Steel (Group) Co., LTD), Yanzhi Fan, Meina Zheng (Jinyuan Community Health Service Center), Faming Liu, Kangning Tang, Ling Zhu (The Second Hospital of Jilin University).

Author contributions

GW, SW, and JL conceived and designed the study. SW and JL developed the protocol, analyzed the data, and drafted the manuscript. TX and HL provided the $PM_{2.5}$ air pollutant database. GW contributed to the interpretation of data and the final approval of publication. The other authors collected data and revised the manuscript. All authors approved the final version before submission.

Funding

This study was supported by the National Key Research and Development Plan of China (Grant No. 2017YFC1309500), the National Natural Science Foundation of China (Grant No. 81370106), Peking University Clinical Research Project (Grant No. PUCRP201303), Beijing Science and Technology Project (Grant Nos. Z121100005512026 and Z221100007422040), the Capital Health Research and Development of Special Fund (Grant Nos. 2016-1-4071 and 2022-1G-4073), Beijing Natural Science Foundation (Grant Nos. 7161013 and M21028). The funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.

Availability of data and materials

Requests for data should be directed to the corresponding author. Patientlevel data will be made available within 5 years of publication. Requests will be assessed before being granted. Data will be anonymized and securely transferred. A data-sharing agreement might be required.

Declarations

Ethics approval and consent to participate

The study was approved by the ethics review committees of the Peking University First Hospital (2018 Number 31). Written informed consent was acquired from all participants.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing financial interest.

Author details

¹Department of Respiratory and Critical Care Medicine, Peking University First Hospital, No.8 Xishiku Street, Xicheng District, Beijing 100034, China. ²Institute of Reproductive and Child Health/National Health Commission Key Laboratory of Reproductive Health and Department of Epidemiology and Biostatistics, School of Public Health, Peking University Health Science Centre, Beijing, China. ³Division of Pulmonary and Critical Care Medicine, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China. ⁴Department of Pulmonary and Critical Care Medicine, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, Shanxi, China. ⁵Respiratory and Critical Care Medicine, Xi'an Jiaotong University Medical College First Affiliated Hospital, Xi'an, Shaanxi, China. ⁶The First Hospital of Qinhuangdao, Qinhuangdao, Hebei, China. ⁷Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.⁸Mindong Hospital of Ningde City, Ningde, Fujian, China. ⁹Tianjin Medical University General Hospital, Tianjin, China. ¹⁰The Second Hospital of Jilin University, Changchun, Jilin, China. ¹¹Department of Respiratory and Critical Care Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.¹²Hebei Key Laboratory of Respiratory Critical Care, Shijiazhuang, Hebei, China. ¹³General Hospital of Taiyuan Iron & Steel (Group) Co., LTD, Taiyuan, Shanxi, China.¹⁴ Jinyuan Community Health Service Center, Taiyuan, Shanxi, China.¹⁵ Jining First People's Hospital, Jining, Shandong, China. ¹⁶Henan Provincial People's Hospital, Zhengzhou, Henan, China. ¹⁷Department of Biostatistics, Peking University First Hospital, Beijing, China.

Received: 27 December 2022 Accepted: 24 April 2023 Published online: 25 May 2023

References

- 1. Guarnieri M, Balmes JR. Outdoor air pollution and asthma. Lancet. 2014;383:1581–92.
- Cohen AJ, Brauer M, Burnett R, Anderson HR, Frostad J, Estep K, Balakrishnan K, Brunekreef B, Dandona L, Dandona R, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017;389:1907–18.
- D'Amato G. Effects of climatic changes and urban air pollution on the rising trends of respiratory allergy and asthma. Multidiscip Respir Med. 2011;6:28–37.
- Mimura T, Ichinose T, Yamagami S, Fujishima H, Kamei Y, Goto M, Takada S, Matsubara M. Airborne particulate matter (PM2.5) and the prevalence of allergic conjunctivitis in Japan. Sci Total Environ. 2014;487:493–9.
- Schultz AA, Schauer JJ, Malecki KM. Allergic disease associations with regional and localized estimates of air pollution. Environ Res. 2017;155:77–85.
- Singh S, Sharma BB, Salvi S, Chhatwal J, Jain KC, Kumar L, Joshi MK, Pandramajal SB, Awasthi S, Bhave S, et al. Allergic rhinitis, rhinoconjunctivitis, and eczema: prevalence and associated factors in children. Clin Respir J. 2018;12:547–56.
- Sugiyama T, Ueda K, Seposo XT, Nakashima A, Kinoshita M, Matsumoto H, Ikemori F, Honda A, Takano H, Michikawa T, Nitta H. Health effects of PM (2.5) sources on children's allergic and respiratory symptoms in Fukuoka, Japan. Sci Total Environ. 2020;709:136023.
- Zhang X, Morrison-Carpenter T, Holt JB, Callahan DB. Trends in adult current asthma prevalence and contributing risk factors in the United States by state: 2000–2009. BMC Public Health. 2013;13:1156.
- Yin P, Brauer M, Cohen AJ, Wang H, Li J, Burnett RT, Stanaway JD, Causey K, Larson S, Godwin W, et al. The effect of air pollution on deaths, disease burden, and life expectancy across China and its provinces, 1990–2017: an analysis for the Global Burden of Disease Study 2017. Lancet Planet Health. 2020;4:e386–98.
- 10. Air pollution prevention and control action plan http://www.gov.cn/ zwgk/2013-09/12/content_2486773.htm. Accessed 10 Oct 2013
- Xue T, Zheng Y, Tong D, Zheng B, Li X, Zhu T, Zhang Q. Spatiotemporal continuous estimates of PM (2.5) concentrations in China, 2000–2016: a machine learning method with inputs from satellites, chemical transport model, and ground observations. Environ Int. 2019;123:345–57.
- 12. WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur. Geneva: World Health Organization https://www.who.int/publications/i/item/9789240034228. Accessed 22 Sept 2021

- Ambient air quality standards https://www.mee.gov.cn/ywgz/fgbz/bz/ bzwb/dqhjbh/dqhjzlbz/201203/t20120302_224165.shtml. Accessed 1 Jan 2016
- Liang L, Cai Y, Barratt B, Lyu B, Chan Q, Hansell AL, Xie W, Zhang D, Kelly FJ, Tong Z. Associations between daily air quality and hospitalisations for acute exacerbation of chronic obstructive pulmonary disease in Beijing, 2013–17: an ecological analysis. Lancet Planet Health. 2019;3:e270–9.
- Bowatte G, Lodge C, Lowe AJ, Erbas B, Perret J, Abramson MJ, Matheson M, Dharmage SC. The influence of childhood traffic-related air pollution exposure on asthma, allergy and sensitization: a systematic review and a meta-analysis of birth cohort studies. Allergy. 2015;70:245–56.
- Anderson HR, Butland BK, van Donkelaar A, Brauer M, Strachan DP, Clayton T, van Dingenen R, Amann M, Brunekreef B, Cohen A, et al. Satellite-based estimates of ambient air pollution and global variations in childhood asthma prevalence. Environ Health Perspect. 2012;120:1333–9.
- Fuertes E, Standl M, Cyrys J, Berdel D, von Berg A, Bauer CP, Krämer U, Sugiri D, Lehmann I, Koletzko S, et al. A longitudinal analysis of associations between traffic-related air pollution with asthma, allergies and sensitization in the GINIplus and LISAplus birth cohorts. PeerJ. 2013;1: e193.
- Fan J, Li S, Fan C, Bai Z, Yang K. The impact of PM2.5 on asthma emergency department visits: a systematic review and meta-analysis. Environ Sci Pollut Res. 2016;23:843–50.
- Nikasinovic L, Just J, Sahraoui F, Seta N, Grimfeld A, Momas I. Nasal inflammation and personal exposure to fine particles PM2.5 in asthmatic children. J Allergy Clin Immunol. 2006;117:1382–8.
- 20. 9 out of 10 people worldwide breathe polluted air, but more countries are taking action https://www.who.int/news-room/detail/02-05-2018-9-out-of-10-people-worldwide-breathe-polluted-air-but-more-countries-are-taking-action. Accessed 2 May 2018
- Huang K, Yang T, Xu J, Yang L, Zhao J, Zhang X, Bai C, Kang J, Ran P, Shen H, et al. Prevalence, risk factors, and management of asthma in China: a national cross-sectional study. Lancet. 2019;394:407–18.
- 22. Samarasekera U. Yaohui Zhao: dedicated to delivering healthy ageing in China. Lancet. 2022;400:1916.
- Wang Y, Liao J, Zhong Y, Zhang C, Li X, Wang G. Predictive value of combining inflammatory biomarkers and rapid decline of FEV (1) for COPD in Chinese population: a prospective cohort study. Int J Chron Obstruct Pulmon Dis. 2019;14:2825–33.
- Kilpeläinen M, Terho EO, Helenius H, Koskenvuo M. Validation of a new questionnaire on asthma, allergic rhinitis, and conjunctivitis in young adults. Allergy. 2001;56:377–84.
- 25. Tracking Air Pollution in China http://tapdata.org.cn/. Accessed 30 Dec 2021
- Geng G, Xiao Q, Liu S, Liu X, Cheng J, Zheng Y, Xue T, Tong D, Zheng B, Peng Y, et al. Tracking air pollution in China: near real-time PM (2.5) retrievals from multisource data fusion. Environ Sci Technol. 2021;55:12106–15.
- 27. Liu X, Zhao C, Shen X, Jin T. Spatiotemporal variations and sources of PM (2.5) in the Central Plains Urban Agglomeration, China. Air Qual Atmos Health. 2022;15:1507–21.
- Feng Y, Ning M, Lei Y, Sun Y, Liu W, Wang J. Defending blue sky in China: effectiveness of the "air pollution prevention and control action plan" on air quality improvements from 2013 to 2017. J Environ Manage. 2019;252: 109603.
- 29. Wüthrich B. Epidemiology of the allergic diseases: are they really on the increase? Int Arch Allergy Appl Immunol. 1989;90(Suppl 1):3–10.
- Chen F, Lin Z, Chen R, Norback D, Liu C, Kan H, Deng Q, Huang C, Hu Y, Zou Z, et al. The effects of PM (2.5) on asthmatic and allergic diseases or symptoms in preschool children of six Chinese cities, based on China, Children, Homes and Health (CCHH) project. Environ Pollut. 2018;232:329–37.
- Hong Z, Guo Z, Zhang R, Xu J, Dong W, Zhuang G, Deng C. Airborne fine particulate matter induces oxidative stress and inflammation in human nasal epithelial cells. Tohoku J Exp Med. 2016;239:117–25.
- 32. Wu P-C, Tsai J-C, Li F-C, Lung S-C, Su H-J. Increased levels of ambient fungal spores in Taiwan are associated with dust events from China. Atmos Environ. 2004;38:4879–86.
- 33. Lee S, Choi B, Yi S-M, Ko G. Characterization of microbial community during Asian dust events in Korea. Sci Total Environ. 2009;407:5308–14.

- Ribeiro H, Guimarães F, Duque L, Noronha F, Abreu I. Characterisation of particulate matter on airborne pollen grains. Environ Pollut. 2015;206:7–16.
- 35. Phosri A, Ueda K, Tasmin S, Kishikawa R, Hayashi M, Hara K, Uehara Y, Phung VLH, Yasukouchi S, Konishi S, et al. Interactive effects of specific fine particulate matter compositions and airborne pollen on frequency of clinic visits for pollinosis in Fukuoka. Japan Environ Res. 2017;156:411–9.
- Ormstad H. Suspended particulate matter in indoor air: relation to allergy. Tidsskr Nor Laegeforen. 2001;121:1344–50.
- Higgins TS, Reh DD. Environmental pollutants and allergic rhinitis. Curr Opin Otolaryngol Head Neck Surg. 2012;20:209–14.
- Chang CJ, Yang HH, Chang CA, Tsai HY. Relationship between air pollution and outpatient visits for nonspecific conjunctivitis. Invest Ophthalmol Vis Sci. 2012;53:429–33.
- Wang YL, Gao W, Li Y, Wang YF. Concentration-dependent effects of PM (2.5) mass on expressions of adhesion molecules and inflammatory cytokines in nasal mucosa of rats with allergic rhinitis. Eur Arch Otorhinolaryngol. 2017;274:3221–9.
- Fujishima H, Satake Y, Okada N, Kawashima S, Matsumoto K, Saito H. Effects of diesel exhaust particles on primary cultured healthy human conjunctival epithelium. Ann Allergy Asthma Immunol. 2013;110:39–43.
- Eguiluz-Gracia I, Mathioudakis AG, Bartel S, Vijverberg SJH, Fuertes E, Comberiati P, Cai YS, Tomazic PV, Diamant Z, Vestbo J, et al. The need for clean air: the way air pollution and climate change affect allergic rhinitis and asthma. Allergy. 2020;75:2170–84.
- 42. Doiron D, de Hoogh K, Probst-Hensch N, Mbatchou S, Eeftens M, Cai Y, Schindler C, Fortier I, Hodgson S, Gaye A, et al. Residential air pollution and associations with wheeze and shortness of breath in adults: a combined analysis of cross-sectional data from Two Large European Cohorts. Environ Health Perspect. 2017;125: 097025.
- Kyvsgaard JN, Krogsgaard Chawes BL, George Horner DL, Hesselberg LM, Melgaard ME, Jensen SK, Malby Schoos AM, Thorsen J, Tingskov Pedersen CE, Brustad N, et al. Risk factors and age-related patterns of asthma-like symptoms in early childhood. J Allergy Clin Immunol Pract. 2023. https:// doi.org/10.1016/j.jaip.2023.02.031.
- 44. Hastert TA, Babey SH, Brown ER, Meng YY. Pets and smoking in the home associated with asthma symptoms and asthma-like breathing problems. Policy Brief UCLA Cent Health Policy Res. 2007;18:1–7.
- Papageorgiou N, Gaga M, Marossis C, Reppas C, Avarlis P, Kyriakou M, Tsipra S, Zeibecoglou K, Tracopoulos G. Prevalence of asthma and asthma-like symptoms in Athens, Greece. Respir Med. 1997;91:83–8.
- 46. Zemp E, Elsasser S, Schindler C, Künzli N, Perruchoud AP, Domenighetti G, Medici T, Ackermann-Liebrich U, Leuenberger P, Monn C, et al. Long-term ambient air pollution and respiratory symptoms in adults (SAPALDIA study). The SAPALDIA Team. Am J Respir Crit Care Med. 1999;159:1257–66.
- Stanek LW, Brown JS, Stanek J, Gift J, Costa DL. Air pollution toxicology–a brief review of the role of the science in shaping the current understanding of air pollution health risks. Toxicol Sci. 2011;120(Suppl 1):S8-27.
- Laney AS, Cragin LA, Blevins LZ, Sumner AD, Cox-Ganser JM, Kreiss K, Moffatt SG, Lohff CJ. Sarcoidosis, asthma, and asthma-like symptoms among occupants of a historically water-damaged office building. Indoor Air. 2009;19:83–90.
- Jarvis D, Newson R, Janson C, Corsico A, Heinrich J, Anto JM, Abramson MJ, Kirsten AM, Zock JP, Bono R, et al. Prevalence of asthma-like symptoms with ageing. Thorax. 2018;73:37–48.
- Strassmann A, de Hoogh K, Röösli M, Haile SR, Turk A, Bopp M, Puhan MA. NO2 and PM2.5 exposures and lung function in swiss adults: estimated effects of short-term exposures and long-term exposures with and without adjustment for short-term deviations. Environ Health Perspect. 2021;129:17009.
- Rice MB, Ljungman PL, Wilker EH, Dorans KS, Gold DR, Schwartz J, Koutrakis P, Washko GR, O'Connor GT, Mittleman MA. Long-term exposure to traffic emissions and fine particulate matter and lung function decline in the Framingham heart study. Am J Respir Crit Care Med. 2015;191:656–64.
- Adar SD, Kaufman JD, Diez-Roux AV, Hoffman EA, D'Souza J, Stukovsky KH, Rich SS, Rotter JI, Guo X, Raffel LJ, et al. Air pollution and percent emphysema identified by computed tomography in the Multi-Ethnic study of Atherosclerosis. Environ Health Perspect. 2015;123:144–51.
- Burke W, Fesinmeyer M, Reed K, Hampson L, Carlsten C. Family history as a predictor of asthma risk. Am J Prev Med. 2003;24:160–9.

- Jung CC, Su HJ. Chemical and stable isotopic characteristics of PM (2.5) emitted from Chinese cooking. Environ Pollut. 2020;267:115577.
- 55. Wong GW, Brunekreef B, Ellwood P, Anderson HR, Asher MI, Crane J, Lai CK. Cooking fuels and prevalence of asthma: a global analysis of phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Lancet Respir Med. 2013;1:386–94.
- 56. Wang J, Janson C, Jogi R, Forsberg B, Gislason T, Holm M, Torén K, Malinovschi A, Sigsgaard T, Schlünssen V, et al. A prospective study on the role of smoking, environmental tobacco smoke, indoor painting and living in old or new buildings on asthma, rhinitis and respiratory symptoms. Environ Res. 2021;192: 110269.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

